Sickle cell disease affects approximately 100,000 people in the US and is most common in African Americans. The Food and Drug Administration (FDA) has approved Casgevy and Lyfgenia, the first ...
LOS ANGELES (KABC) -- It's been more than a month since the FDA approved two milestone gene-editing treatments for sickle cell disease, but lining up patients for these therapies will be a challenge ...
Editor’s Note: Elizabeth Yuko, Ph.D., is a bioethicist and writer whose work has appeared in The New York Times, Rolling Stone, The Washington Post, The Atlantic and elsewhere. She is also an adjunct ...
An illustration of sickled and normal red blood cells. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.
Climate Compass on MSN
CRISPR and the future: Can we edit out genetic diseases?
We're living in a moment where science fiction is becoming medical reality. Imagine a world where doctors can simply rewrite ...
COLUMBUS, Ga. (WRBL) — September is Sickle Cell Awareness Month, and millions of people worldwide are living with the disease. But advances in treatment are being made. WRBL News 3 anchor Cameron ...
The U.S. government will test whether centrally coordinating insurance coverage can help people with sickle cell disease access expensive new gene therapies for the inherited blood condition. Two such ...
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “bluebird”) today announced the details of its U.S. commercial infrastructure to support timely, equitable ...
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or “bluebird”) today announced new and updated efficacy, safety and health-related quality of life (HRQoL) data ...
Editas Therapeutics is developing a gene-editing therapy called reni-cel for Sickle Cell Disease and beta-thalassemia. The competitive landscape for gene-editing therapies for SCD is strengthening ...
The past couple of years have been eventful for Bluebird Bio (NASDAQ: BLUE). In 2022, the gene-editing specialist earned approval for two therapies in the U.S.: Zynteglo, which treats the beta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback